Merck announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the phase III KeyVibe-010 trial.
Merck announced positive topline results from the pivotal phase III MK-3475A-D77 trial.
Merck discontinues arm of phase III trial evaluating vibostolimab + pembrolizumab in adjuvant high-risk melanoma
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Clinical and real-world data for the 9-valent human papillomavirus vaccine, Gardasil 9, evaluating the burden and incidence of certain HPV-related cancers and diseases, were presented at the International Papillomavirus Conference 2024 in Edinburgh, UK, from Nov. 12-15.
Addition of the immunotherapy drug pembrolizumab (Keytruda) to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre.
Promising preliminary results from an ongoing investigator-initiated phase I clinical trial evaluating the safety and efficacy of a combined regimen of Keytrua (pembrolizumab) and Lymphir (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors were announced.
Modifi Biosciences Inc., a Yale University spinout company formed in 2021 that develops direct DNA-modification-enabled cancer therapeutics, has been acquired by Merck.
The European Commission has approved two new indications for Keytruda (pembrolizumab), an anti-PD-1 therapy, in gynecologic cancers.
